

Axinn Patent Attorneys Talk ACA Pushback and the BPCIA

PUBLICATIONS | LESS THAN 1 MIN READ


May 4, 2020

The Center for Biosimilars

On May 4, Axinn partner Ted Mathias participated in a video interview with *The Center for Biosimilars*. He discussed the overall pushback to the Affordable Care Act (ACA) and what that means for the Biologics Price Competition and Innovation Act (BPCIA).

Click to access [part 1](#), [part 2](#), and [part 3](#) of the interview.

Related People



Ted Mathias

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS